What Xvivo Perfusion does

Xvivo Perfusion AB (publ) is a Sweden-based publicly traded medtech company (OTCMKTS: XVIPY), founded in 1998 and headquartered in Gothenburg, that develops ex vivo organ perfusion and preservation technology for use in transplantation. The company's core offering consists of machine perfusion systems for donor lungs, hearts, kidneys, and livers; single-use disposables and consumables required for each procedure; and a CE-marked organ storage device. Its clinical value proposition centers on enabling transplant centers and organ procurement organizations (OPOs) to assess, preserve, and rehabilitate marginal donor organs that would otherwise be rejected — for example, lungs initially declined by multiple transplant centers were successfully transplanted after nearly five hours of machine perfusion at Indiana Donor Network in January 2026.

The company generates revenue through three streams: capital equipment sales of perfusion machines, recurring procedure-based revenue from single-use disposables, and professional services including education, training, and technical support. Go-to-market is enterprise field sales directed at transplant centers and OPOs in Europe (Sweden, Italy via the XVIVO S.r.l. subsidiary) and the United States (via the Star Teams Inc. subsidiary). Pricing is quote-based and not publicly disclosed. Strategic positioning is reinforced by recent M&A: Star Teams Inc. (US organ recovery services, acquired November 2021 for USD 12.61M plus earn-out up to USD 13.75M) and XVIVO S.r.l. (Italian distributor with CE-marked organ storage device, acquired November 2022 for up to EUR 12.0M plus EUR 2.4M earn-out). The company is currently scaling beyond its lung franchise, with planned 2026 launches in heart, kidney, and liver categories in the U.S. market under a reorganized executive structure that elevates U.S. strategy and business development.

Name

Xvivo Perfusion

Legal name

Xvivo Perfusion AB (publ)

Website

https://xvivoperfusion.com

Company type

Public

Founded year

1998

Operating status

Operating

Headcount range

101–250 employees

Short description

Xvivo Perfusion AB is a Sweden-based publicly traded medtech company that develops ex vivo organ perfusion machines, disposables, and CE-marked storage devices for transplant centers and organ procurement organizations, enabling use of marginal donor lungs, hearts, kidneys, and livers across Europe and the United States.

Ownership category

akta.pro rank

Product category

Organ Perfusion and Transplant Medical Devices

NAICS

Surgical and Medical Instrument Manufacturing (339112), Surgical Appliance and Supplies Manufacturing (339113)

SIC

Surgical & Medical Instruments & Apparatus (3841), Pumps & Pumping Equipment (3561), Wholesale-Medical, Dental & Hospital Equipment & Supplies (5047)

akta.pro primary industry

Mechanical Circulatory Support (VAD, IABP, ECMO) (HLAHAFAG)

akta.pro secondary industry

Infusion Pumps (Ambulatory/Stationary) (HLAHAIAF)

Keywords

• Organ perfusion systems
• Organ preservation devices
• Transplant medical devices
• Perfusion consumables
• Ex vivo organ storage

Headquarters

HQ city

Göteborg

HQ country

Sweden

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Supply Chain, Operations, Marketing or Sales

Revenue model

1. Perfusion Machines and Systems: Sale of machine perfusion devices and systems used for organ preservation and assessment. Revenue derived from capital equipment sales to transplant centers and organ recovery organizations.
2. Disposables and Consumables: Recurring revenue from single-use disposables and consumables required for organ perfusion procedures, providing recurring revenue streams tied to transplant volume.
3. Service and Support: Education, training, and technical support services for perfusion equipment, including service contracts and on-site support for organ recovery operations.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels3 records

Core offering

Xvivo Perfusion develops, manufactures, and sells ex vivo organ perfusion machines, single-use disposables, and CE-marked organ storage devices used by transplant centers and organ procurement organizations to preserve, assess, and recondition donor organs (lungs, heart, kidney, liver) before transplantation. The portfolio is complemented by organ recovery services (Star Teams in the US), CE-marked storage devices (via XVIVO S.r.l. in Italy), and education, training, and technical support.

Product overview

Xvivo Perfusion is a medtech company specializing in ex vivo organ perfusion technology for organ transplantation. The company's portfolio consists of perfusion machines (for lungs, heart, kidney, and liver), single-use perfusion disposables, and CE-marked organ storage devices. The product architecture centers on a core perfusion platform supported by consumable disposables. The company has expanded through acquisitions including Star Teams Inc. (US organ recovery services, 2021) and XVIVO S.r.l. (Italian distributor with CE-marked storage device, 2022). Upcoming product launches are planned in heart, kidney, and liver categories, with the company pioneering in-house machine perfusion capabilities for organ recovery organizations.

Differentiator

Problem solved

Functional benefit

Products and services

• In-House Lung Machine Perfusion System Machine perfusion system enabling organ recovery organizations to perform in-house perfusion of marginal donor lungs, improving organ function before transplantation. Developed for use by OPOs and recovery teams.
• Organ Perfusion Machines Ex vivo perfusion machines used for preservation and reconditioning of donor organs across multiple organ types including lungs, heart, kidney, and liver. Enable organ viability assessment and preservation between donation and transplantation. Sold to transplant centers and organ recovery organizations.
• Perfusion Disposables Single-use consumables required for organ perfusion procedures, including tubing sets, cannulas, and preservation solutions used with Xvivo's perfusion machines. Generates recurring revenue tied to transplant procedure volume.
• CE-Marked Organ Storage Device CE-marked medical device for ex vivo organ storage and transport during the transplantation process. Part of the perfusion machine portfolio acquired through the Avionord transaction, enhancing service offerings in the European market.
• Star Teams Organ Recovery Services US organ recovery services provided by Star Teams Inc., acquired in November 2021. Complements Xvivo's perfusion technology portfolio by delivering organ recovery expertise to US transplant centers and OPOs.

Quantifiable outcome

• Enables successful transplantation of lungs initially rejected by multiple regional transplant centers
• +1 more outcomes

Named customers1 record

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Two partnerships are on record, tiered core and minor.

• Indiana Donor NetworkcoreStrategic or Co-development Partner · 29 January 2026Partnership with Indiana Donor Network for deployment of in-house machine perfusion system for marginal lungs. Indiana Donor Network became the first U.S. organ recovery organization with in-house lung perfusion capability, enabling successful transplantation of lungs initially rejected by multiple transplant centers. This partnership positions the collaboration to enable further lifesaving transplants from previously rejected organs.
• Perfusion SolutionminorStrategic or Co-development Partner · 29 January 2026Wisconsin-based partnership for machine perfusion technology deployment. Perfusion Solution collaborated with XVIVO and Indiana Donor Network on the first U.S. in-house machine perfusion system for marginal lungs, contributing to the successful transplant in Indiana on January 29, 2026.

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Market position

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Subsidiaries2 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A3 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Xvivo Perfusion